Clinical Trials6 July 2026· 9 min read
DTP3 Signals A New Route for Relapsed Myeloma Care
DTP3 multiple myeloma development targets a cancer-restricted NF-kB survival switch. Could this first-in-class peptide open a new lane for relapsed and refractory patients?
By Tom Okafor, Clinical Trials Correspondent